Use of AICA riboside compounds for the treatment and prevention of tissue damage due to decreased blood flow.

摘要

Methods of preventing tissue damage associated with decreased blood flow in a human by administering AICA riboside or a prodrug thereof in an amount which provides a blood plasma concentration of between 1 <0>g/ml and 20 <0>g/ml of AICA riboside for a time sufficient to reduce the risk of said tissue damage in said human. Methods of preventing an adverse clinical outcome, such as an adverse cardiovascular arid/or cerebrovascular event, in a patient at risk for such outcome by administering AICA riboside or a prodrug thereof in an amount which provides a blood plasma concentration of between 1 <0>g/ml and 20 <0>g/ml of AICA riboside for a time sufficient to reduce the risk for said patient.